De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission.

Abstract

Peripheral T-cell lymphoma (PTCL) is an aggressive form of non-Hodgkin's lymphoma (NHL), associated with poor prognosis and without standard approach to treatment. Denileukin diftitox (Ontak) is a synthetic fusion protein combining the receptor-binding domain of interleukin-2 to the enzymatically active portion of diphtheria toxin. While approved for the treatment of cutaneous T-cell lymphoma, it has demonstrated activity in non-Hodgkin's lymphomas of both T-cell and B-cell origin. This report documents the first case of de novo maintenance therapy with denileukin diftitox sustaining an ongoing complete response at the molecular level for 2 years in a patient with PTCL.

• Authors: Bryan Y Wong, Yupo Ma, Robert Fitzwilson, Nam H Dang
• Journal: American journal of hematology (Am J Hematol) Vol. 83 Issue 7 Pg. 596-8 (Jul 2008) ISSN: 1096-8652 [Electronic] United States
• PMID: 18383317 (Publication Type: Case Reports, Journal Article)
• Copyright: (c) 2008 Wiley-Liss, Inc.

Chemical References

• Diphtheria Toxin
• Interleukin-2
• Recombinant Fusion Proteins
• denileukin diftitox

Topics

• Diphtheria Toxin (therapeutic use)
• Humans
• Interleukin-2 (therapeutic use)
• Lymphoma, T-Cell, Peripheral (drug therapy, pathology)
• Male
• Middle Aged
• Recombinant Fusion Proteins (therapeutic use)
• Remission Induction